ASH 2023 – Stephan Stilgenbauer

Stephan Stilgenbauer discusses the current evidence regarding the treatment of Richter transformation with modern agents and reviews the findings of the RT1 trial presented at the ASH 2023 meeting. Finally, he highlights future combinations of novel agents like adding the next-generation BCL-2 inhibitor sonrotoclax to tislelizumab plus zanubrutinib which will be investigated in the amendment of the RT1 trial or the use of the non-covalent BTK inhibitor pirtobrutinib combined with epcoritamab, a bispecific antibody, that will be in the focus of the international RT2 trial.

Here is the full ASH 2023 report.

More posts

Advancing care in Waldenström macroglobulinemia: Clinical and real-world perspectives

Recent advances have transformed the management of Waldenström macroglobulinemia (WM), particularly with the advent of targeted therapies such as Bruton tyrosine kinase (BTK) inhibitors. These innovations have addressed longstanding challenges including resis­tance, intolerance, and the need for personalized approaches (enabling therapy also for those deemed unfit for chemotherapy).

Follicular lymphoma: Efficacy and safety updates

In the context of follicular lymphoma treatment, there is a clear unmet need for patients who have experienced early progression (progression within 24 months of front-line therapy, POD24), as well as those who are refractory to treatment and present with other high-risk features. At ASH 2024, promising efficacy and safety data were reported for the five molecules nemtabrutinib, zanubrutinib, BGB-16673, epcoritamab, and mosunetuzumab [1-6].

Pushing the boundaries further in the management of CLL

In patients with treatment-naïve chronic lymphocytic leukemia (CLL), the multicenter, open-label, randomized, phase III AMPLIFY trial was initiated to evaluate fixed-duration treatment with acalabrutinib plus venetoclax ± obinutuzumab compared to investigator’s choice of chemoimmunotherapy (CIT).

Editorial – ASH 2024

The 66th Annual Meeting of the American Society of Hematology (ASH), held as a hybrid event from December 7th to 10th, 2024, in San Diego, California, USA, set a new benchmark with over 7,950 abstracts accepted for presentation.